2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Université Paris Cité · McGill University Health Centre · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
433
total citations
- FWCI
- 85.44
- Percentile
- 100%
- References
- 105
Citations per year
Authors
106- DFDominique FargeCorresponding
Université Paris Cité, McGill University Health Centre, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis
- CFCorinne Frère
Inserm, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Unité de recherche sur les maladies cardiovasculaires et métaboliques, Groupe de REcherche en Cardio Oncologie
- JMJean M. Connors
Brigham and Women's Hospital, Harvard University
- AAAlok A. Khorana
Cleveland Clinic
- AKAjay K. Kakkar
Faculty (United Kingdom), Thrombosis Research Institute, University College London
Topics & keywords
Topics
Keywords
- Medicine
- Thrombosis
- Rivaroxaban
- Cancer
- Venous thrombosis
- Intensive care medicine
- Apixaban
- Internal medicine
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- TPTeva Pharmaceutical Industries
- APAlnylam Pharmaceuticals
- CCelgene
- CBCSL Behring
- ISInternational Society on Thrombosis and Haemostasis
- IIncyte
- NSNippon Shinyaku
- DDaiichi-Sankyo
- APAstellas Pharma
- SASociété Académique de Genève
- SServier
- LPLEO Pharma
- NINational Institutes of HealthAwards: COVID-19, UO1 HL 144302-01
- DSDaiichi Sankyo Europe